According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...
Extended pelvic lymph node dissection prolongs biochemical recurrence-free and metastasis-free survivals in localized prostate cancer.
Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC) No significant financial ...
A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...
Using real-world data, a team of U.S.-based investigators analyzed survival outcomes among an independent cohort of patients with metastatic urothelial cancer (UC) treated with immune checkpoint ...